Research

Hormonal

SGLT2 inhibitors lower blood pressure primarily through early osmotic diuresis and volume contraction, with sustained effects driven by reduced arterial stiffness and improved endothelial function.

If you have heart failure or diabetes, SGLT2 inhibitors (like Jardiance or Farxiga) will likely lower your blood pressure slightly, but this is a bonus, not the main reason for taking them. The benefit comes from reducing fluid volume and improving artery health, not just sugar control.

GoodSupportsHIGH confidence
SGLT2is exert antihypertensive effects through an interplay of hemodynamic and vascular mechanisms... The resultant BP decline is typically observed within days of therapy initiation... SGLT2is are proven to decrease arterial stiffness... These improvements in arterial compliance complement the early hemodynamic effects driven by natriuresis and volume contraction.
Andrej Belančić et al. · British Journal of Clinical Pharmacology · 2025

Why this rating

Supported by multiple trial types (CVOTs, HF trials) and real-world data, though dedicated BP trials are noted as lacking.

Source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

Andrej Belančić et al. · British Journal of Clinical Pharmacology · 2025

DOI 10.1002/bcp.70378

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →